Molecular genetics in hypertrophic cardiomyopathy: Towards individualized management of the disease

Expert Review of Molecular Diagnostics

Volumn 6, Issue 1, 2006, Pages 65-78

  Charron, Philippe ^a   Komajda, Michel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Gene; Genetic counseling; Hypertrophic cardiomyopathy; Predictive diagnosis; Prenatal diagnosis; Prognosis; Sarcomere

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; SPIRONOLACTONE; VERAPAMIL;

CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIAGNOSTIC TEST; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INHERITANCE; MOLECULAR GENETICS; NONHUMAN; PATHOPHYSIOLOGY; PEDIGREE; PENETRANCE; PRENATAL DIAGNOSIS; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SUDDEN DEATH; SYMPTOM; SYSTOLE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN; DISEASE SUSCEPTIBILITY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; RISK FACTORS;

EID: 33645345971     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.1.65     Document Type: Review

References (96)

1. Richardson P, McKenna W, Bristow M et al. Hypertrophic cardiomyopathy, a systematic review. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 93, 841-842 (1996).
2. Maron BJ. Hypertrophic cardiomyopathy, a systematic review. JAMA 287, 1308-1320 (2002). State-of-the-art review describing cardiologic aspects of hypertrophic cardiomyopathy (HCM).
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 363, 1881-1891 (2004).
4. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358, 1627-1637 (2001).
5. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92, 785-789 (1995).
6. Zou Y, Song L, Wang Z et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am. J. Med. 116(1), 14-18 (2004).
7. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 276, 199-204 (1996).
8. Wigle ED. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. Heart 86, 709-714 (2001).
9. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology/European Society of Cardiology: clinical expert consensus document on hypertrophic cardiomyopathy. Eur. Heart J. 24(21), 1965-1991 (2003). Comprehensive review describing cardiologic aspects of HCM, especially prognostic evaluation and therapeutic strategy.
10. McKenna WJ, Spirito P, Desnos M et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77, 130-132 (1997).
11. Charron P, Dubourg O, Desnos M et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 96, 214-219 (1997).
12. Savage DD, Seides SF, Clark CE et al. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 58, 402-408 (1978).
13. 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10(11), 1215-1220 (2001).
14. Murphy RT, Mogensen J, McGarry K et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J. Am. Coll. Cardiol. 45(6), 922-930 (2005).
15. Maron BJ, Nichols PF III, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am. J. Cardiol. 53, 1087-1094 (1984).
16. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am. J. Cardiol. 81, 1339-1344 (1998).
17. Mörner S, Hellman U, Suhr OB, Kassam E, Waldenström A. Amyloid heart disease mimicking hypertrophic cardiomypathy. J. Int. Med. 258, 225-230 (2005).
18. Charron P, Villard E, Sebillon P et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 90(8), 842-846 (2004).
19. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105, 1407-1411 (2002).
20. Murphy RT, Thaman R, Blanes JG et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur. Heart J. 26(2), 187-192 (2005).
21. Maron BJ, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102(8), 858-864 (2000).
22. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357(9254), 420-424 (2001).
23. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J. Am. Coll. Cardiol. 41(6), 987-993 (2003).
24. Pelliccia A, Fagard R, Bjorstad HH et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 26(14), 1422-1445 (2005).
25. Maron BJ, Chaitman BR, Ackerman MJ et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109(22), 2807-16 (2004).
26. Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342(6), 365-373 (2000). First large evaluation of the efficacy of cardioverter defibrillators in HCM.
27. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 90(5), 570-575 (2004).
28. Ommen SR, Maron BJ, Olivotto I et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 46(3), 470-476 (2005).
29. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies. Circulation 104, 2113-2116, 2249-2252 (2001).
30. Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a β-cardiac myosin heavy chain gene missense mutation. Cell 62, 999-1006 (1990).
31. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 33, 655-670 (2001). State-of-the-art review discussing genetic aspects of HCM and physiopathologic concepts.
32. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodelling. Ann. Rev. Hum. Genet. 6, 185-216 (2005).
33. Watkins H. Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation 107, 1344-1346 (2003).
34. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ. Res. 83, 580-593 (1998).
35. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Biophys. Res. Commun. 262, 411-417 (1999).
36. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17(6), 524 (2001).
37. Carniel E, Taylor MR, Sinagra G et al. α-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112(1), 54-59 (2005).
38. Geier C, Perrot A, Ozcelik C et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107, 1390-1395 (2003).
39. Hayashi T, Arimura T, Itoh-Satoh M et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44(11), 2192-2201 (2004).
40. Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for a molecular diagnosis strategy. Circulation 107, 2227-2232 (2003).
41. Song L, Zou Y, Wang J et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin. Chim. Acta. 351(1-2), 209-216 (2005).
42. Erdmann J, Daehmlow S, Wischke S et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin. Genet. 64(4), 339-349 (2003).
43. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein C: its role in physiology and disease. Circ. Res. 94(10), 1279-1289 (2004).
44. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J. Clin. Invest. 91(6), 2861-2865 (1993).
45. Rottbauer W, Gautel M, Zehelein J et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy: characterization of cardiac transcript and protein. J. Clin. Invest. 100(2), 475-482 (1997).
46. Watkins H, Seidman CE, Seidman JG, Feng HS, Sweeney HL. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J. Clin. Invest. 98(11), 2456-2461 (1996).
47. Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J. Clin. Invest. 103(10), 1459-1467 (1999).
48. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing β myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 95, 1409-1414 (1995).
49. 2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy. J. Biol. Chem. 274, 8806-8812 (1999).
50. Geisterfer-Lowrance AA, Christe M, Conner DA et al. A mouse model of familial hypertrophic cardiomyopathy. Science 272, 731-734 (1996). First report of an animal model for HCM, and the analysis of functional consequences.
51. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Invest. 102, 1292-1300 (1998).
52. Marian AJ, Zhao G, Seta Y, Roberts R, Yu QT. Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ. Res. 81(1), 76-85 (1997).
53. Carrier L, Knoll R, Vignier N et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc. Res. 63(2), 293-304 (2004).
54. Lin D, Bobkova A, Homsher E, Tobacman LS. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J. Clin. Invest. 97(12), 2842-2848 (1996).
55. 2+ regulation of thin filament motility. Biochem. Biophys. Res. Commun. 236(3), 760-764 (1997).
56. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J. Clin. Invest. 90, 1666-1671 (1992).
57. Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in α tropomyosin that causes hypertrophic cardiomyopathy. Circulation 91, 2302-2305 (1995).
58. Forissier JF, Richard P, Briault S et al. First description of germline mosaicism in familial hypertrophic cardiomyopathy. J. Med. Genet. 37(2), 132-134 (2000).
59. Richard P, Isnard R, Carrier C et al. Double heterozygosity for mutations in the β myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J. Med. Genet. 36, 542-545 (1999).
60. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation 102(16), 1950-1955 (2000).
61. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 105(20), 2337-2340 (2002).
62. Charron P, Carrier L, Dubourg O et al. Penetrance of familial hypertrophic cardiomyopathy. Genet. Couns. 8(2), 107-114 (1997).
63. Watkins H, McKenna WJ, Thierfelder L et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332, 1058-1064 (1995).
64. Watkins H, Rosenzweig A, Hwang DS et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326, 1108-1114 (1992).
65. Charron PH, Dubourg O, Desnos M et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin binding protein C gene. Circulation 97, 2230-2236 (1998).
66. Nimura H, Bachinski L, Sangwatanaroj S et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 338, 12448-12457 (1998).
67. Maron BJ, Niimura H, Casey SA et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J. Am. Coll. Cardiol. 38(2), 315-321 (2001).
68. Charron P, Dubourg O, Desnos M et al. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the β-myosin heavy chain genes. Eur. Heart J. 19(1), 139-145 (1998).
69. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation 98(5), 391-397 (1998).
70. Niimura H, Patton KK, McKenna WJ et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105(4), 446-451 (2002).
71. Mogensen J, Murphy RT, Kubo T et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44(12), 2315-2325 (2004).
72. Flavigny J, Richard P, Isnard R et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J. Mol. Med. 76(3-4), 208-214 (1998).
73. Poetter K, Jiang H, Hassanzadeh S et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genet. 13(1), 63-69 (1996).
74. Semsarian C, Healey MJ, Fatkin D et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 33(11), 2055-2060 (2001).
75. Lechin M, Quinones MA, Omran A et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 92, 1808-1812 (1995).
76. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 17(3), 242-252 (2002).
77. Ko YL, Tang TK, Chen JJ, Hshieh YY, Wu CW, Lien WP. Idiopathic hypertrophic cardiomyopathy in identical twins. Morphological heterogeneity of the left ventricle. Chest 102(3), 783-785 (1992).
78. Tesson F, Richard P, Charron P et al. Genotype-phenotype analysis in four families with mutations in β-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Hum. Mutat. 12, 385-392 (1998).
79. van Langen IM, Birnie E, Leschot NJ, Bonsel GJ, Wilde AA. Genetic knowledge and counselling skills of Dutch cardiologists: sufficient for the genomics era? Eur. Heart J. 24(6), 560-566 (2003).
80. Charron P, Heron D, Gargiulo M et al. Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience. J. Med. Genet. 39, 741-746 (2003). Comprehensive review of genetic counselling in HCM.
81. Maron BJ, Moller JH, Seidman CE et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marian syndrome. Am. Heart J. Circulation 98, 1460-1471 (1998).
82. Roberts R, Ryan TJ. Task force 3: clinical research in a molecular era and the need to expand its ethical imperatives. J. Am. Coll. Cardiol. 31, 942-949 (1998).
83. Ryan MP, French J, Al-Mahdawi S et al. Genetic testing for familial hypertrophic cardiomyopathy in newborn infants. An ethical debate. Br. Med. J. 310, 856-858 (1995).
84. Vosberg HP. Genetic counselling for hypertrophic cardiomyopathy: are we ready for it? Curr. Control Trials Cardiovasc. Med. 1, 41-44 (2000).
85. Marian AJ, Roberts R. To screen or not to screen is not the question - it is when and how to screen. Circulation 107, 2171-2174 (2003).
86. Blair E, Redwood C, de Jesus Oliveira M et al. Mutations of the light meromyosin domain of the β-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ. Res. 90(3), 263-269 (2002).
87. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44, 2125-2132 (2004).
88. Fagard R. Athlete's heart. Heart 89(12), 1455-1461 (2003).
89. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur. J. Hum. Genet. 8, 731-738 (2000).
90. Evers-Kiebooms G, Welkenhuysen M, Claes E, Decruyenaere M, Denayer L. The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. Soc. Sci. Med. 51, 831-841 (2000).
91. Varnava A, Baboonian C, Davison F et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart 82, 621-624 (1999).
92. Clarke A, Harper P. Genetic testing for hypertrophic cardiomyopathy, letter. N. Engl. J. Med. 327, 1175 (1992).
93. ASHG/ACMG report. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 57, 1233-1241 (1995).
94. Yagel S, Anteby E. A rational approach to prenatal screening and intervention. Hum. Reprod. 13, 1125-1126 (1998).
95. Simpson SA, Zoeteweij MW, Nys K et al. Prenatal testing for Huntington's disease: a European collaborative study. Eur. J. Hum. Genet. 10, 689-693 (2002).
96. Charron P, Heron D, Gargiulo M et al. Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case. Prenat. Diagn. 24, 701-703 (2004).